# Response to Standard PBC Treatment at 1 Year Linked to Lower Long-Term Risks

Source: [MedPageToday.com - medical news for physicians](https://www.medpagetoday.com/meetingcoverage/aasld/123864) · 2026-11-12 · Medicine
Page: https://themorning.science/story/response-to-standard-pbc-treatment-at-1-year-linked-to-lower-long-term-risks-d74d51d80fe50b96
Kind: research · Impact: medium

## In brief

- A biochemical response to ursodeoxycholic acid (UDCA) at 12 months was associated with lower 5-year risks of hepatic decompensation and mortality in patients with primary biliary cholangitis (PBC).
- The finding comes from a propensity-matched landmark analysis.

## Why it matters

It suggests that response to standard UDCA therapy at one year may help clinicians identify PBC patients with better long-term outcomes.

## Coverage

- [Response to Standard PBC Treatment at 1 Year Linked to Lower Long-Term Risks](https://www.medpagetoday.com/meetingcoverage/aasld/123864) — MedPageToday.com - medical news for physicians, 2026-11-12

Tags: primary biliary cholangitis, ursodeoxycholic acid, liver disease, hepatology, treatment response

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science